Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the human anti-EDB antibody L19, fused to human TNF, a strong pro-inflammatory cytokine. Recombinant TNF (Beromun®, Boehringer Ingelheim) has so far been approved only for certain clinical applications.
In a phase Ib clinical trial the combination of Fibromun and doxorubicin was shown to be well tolerated and to confer efficacy in heavily pretreated soft tissue sarcoma patients evidenced by (i) induction of wide areas of tumor necrosis, (ii) significant shrinkage of metastatic lesions and (iii) cases with partial and complete response.
In a recently established collaboration with the University Hospital Zurich, the murine surrogate of Fibromun has demonstrated a striking single-agent anti-cancer activity in preclinical models bearing orthotopic glioblastoma. The treatment induced long-term tumor eradications in a proportion of the treated animals. These results provided a strong rationale for the ongoing clinical development of Fibromun in patients with brain tumors.
ONGOING CLINICAL TRIALS
Weiss et al., (2020) Sci Transl Med, 12 (564):eabb2311
Probst et al., (2019) Clin Cancer Res, 25, 698-709
Probst et al., (2017) Cancer Res, 77, 3644-3654
Hemmerle and Neri (2013) Br J Cancer, 109, 1206-13
Papadia et al. (2013) J Surg Oncol, 107, 173-179
Spitaleri et al (2013) J Cancer Res Clin Onc, 139, 447-455
Balza et al. (2010) Int J Cancer, 127, 101-10
Schliemann (2009) Leuk Res, 33, 1718-22
Balza et al. (2006) Clin Cancer Res, 12, 2575-2582
Borsi et al. (2003) Blood, 102, 4384-4392
Halin et al. (2003) Cancer Res, 63, 3202-10
Santimaria (2003) Clin Cancer Res, 9, 571-9
Castellani et al. (2002) Am J Pathol, 161, 1695-1700